Curis Inc. (CRIS) had a rough trading day for Friday September 27 as shares tumbled 5.18%, or a loss of $-0.13 per share, to close at $2.38. After opening the day at $2.54, shares of Curis Inc. traded as high as $2.54 and as low as $2.25. Volume was 156,668 shares over 752 trades, against an average daily volume of n/a shares and a total float of 33.2 million.
As a result of the decline, Curis Inc. now has a market cap of $79.02 million. In the last year, shares of Curis Inc. have traded between a range of $2.90 and $0.60, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Curis Inc. is based out of Lexington, MA and has some 31 employees. Its CEO is James E. Dentzer.